Adjuvant chemotherapy in average-risk adult medulloblastoma patients improves survival: a long term study
Abstract Background Medulloblastoma is extremely rare in adults. The role of chemotherapy for average-risk adult patients remains controversial. Surgery and radiotherapy provide a significant disease control and a good prognosis, but about 25% of average-risk patients have a relapse and die because...
Main Authors: | E. Franceschi, S. Minichillo, A. Mura, A. Tosoni, M. Mascarin, C. Tomasello, S. Bartolini, A. A. Brandes |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-08-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-020-07237-x |
Similar Items
-
Postoperative Chemotherapy for Medulloblastoma
by: J Gordon Millichap
Published: (2005-03-01) -
Correlation between MRI characteristics of medulloblastoma with histopathological subtypes and 2-year survival
by: Intan Zariza Hussain, et al.
Published: (2020-01-01) -
Questions and answers in the management of children with medulloblastoma over the time. How did we get here? A systematic review
by: Marta P. Osuna-Marco, et al.
Published: (2023-06-01) -
Medulloblastoma in a 6 Year Old Mixed Breed Dog: Surgical Debulking and Chemotherapy
by: Rachel Lampe, et al.
Published: (2019-11-01) -
Adult Medulloblastoma Demographic, Tumor and Treatment Impact since 2006: A Canadian University Experience
by: Maria Camila Quinones, et al.
Published: (2021-08-01)